Published Date: 02 Mar 2023
A link between depression and changes in various immune systems in the blood has been discovered by researchers from the Department of Integrative Epidemiology at MRC, University of Bristol. The results of this research...
Read Full NewsMiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.
Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.
1.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
2.
Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.
3.
Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.
4.
New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.
5.
According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.
1.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
2.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
3.
Gynecologic Oncology: Advances, Education, and Clinical Excellence
4.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
5.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation